Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3903640 | 0.81 | CYP1A2 (0.74) | CYP1A2POLBALDH1A1HTTLMNA | |
| SCHEMBL10352637 | 0.80 | POLB (0.54) | CYP1A2POLBALDH1A1HTTMAPT | |
| SCHEMBL2338533 | 0.76 | CYP1A2 (0.71) | CYP1A2POLBALDH1A1HTTLMNA | |
| SCHEMBL3909586 | 0.74 | CYP1A2 (0.50) | CYP1A2POLBALDH1A1HTTLMNA | |
| SCHEMBL3903445 | 0.74 | FYN (0.37) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2978585 | 0.71 | ALDH1A1 (0.39) | POLBALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL8751846 | 0.71 | KMT2A (0.36) | ALDH1A1LMNAMEN1KMT2ATSHR | |
| SCHEMBL13224714 | 0.71 | MEN1 (0.33) | SMN1; SMN2FFAR1MEN1KMT2A | |
| SCHEMBL2981329 | 0.71 | MEN1 (0.36) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3905547 | 0.70 | CYP1A2 (0.49) | CYP1A2POLBALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | CYP1A2 135/4885POLB 3927/4885ALDH1A1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.